Compare Berkshire Hathaway Inc Class B (BRK.B) vs Ginkgo Bioworks Holdings Inc (DNA) Price & Performance

BRK.B trades at $510.23, down 3.67% today, with technical indicators showing a bullish trend from moving averages but neutral oscillators. Analyst consensus is positive with 57% buy ratings. The stock's fundamentals reflect Berkshire Hathaway's diversified holdings and strong cash flow, though specific valuation ratios are not provided in the snapshot.

The outlook remains favorable due to strong analyst support and technical momentum, but risks include market volatility and economic uncertainties. Investment opportunity lies in the company's robust business model, while caution is advised near current resistance levels.

Ginkgo Bioworks (DNA) trades at $7.29, down 4.71% with bearish technical signals. The company reported Q2 2026 revenue of $20 million, down 48% year-over-year, continuing its strategic pivot to autonomous labs. Despite beating EPS expectations in two of the last three quarters, DNA shows negative profitability with -219.6% net income margin and negative cash flow. Analyst sentiment is mixed with 45% buy ratings but significant institutional selling pressure.

DNA faces substantial execution risk during its business transition, with declining revenue and persistent losses offset by potential in autonomous laboratory technology. The stock's current valuation at 3.61x sales appears stretched given negative earnings, requiring successful operational turnaround for sustainable recovery. Near-term catalysts depend on revenue stabilization and cost management improvements.